Novel therapeutic approaches in primary hyperoxaluria

References

• Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med. 2013;369:649–658.
   PubMed Web of Science ®Google Scholar
• Habbig S, Beck BB, Hoppe B. Nephrocalcinosis and urolithiasis in children. Kidney Int. 2011;80:1278–1291.
   PubMed Web of Science ®Google Scholar
• Cregeen DP, Williams EL, Hulton S, et al. Molecular analysis of the glyoxylate reductase (GRHPR) gene and description of mutations underlying primary hyperoxaluria type 2. Hum Mutat. 2003;22:497.
   PubMed Web of Science ®Google Scholar
• Belostotsky R, Seboun E, Idelson GH, et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet. 2010;87:392–399.
   PubMed Web of Science ®Google Scholar
• Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol. 2012;8:467–475.
   PubMed Web of Science ®Google Scholar
• Mulay SR, Kulkarni OP, Rupanagudi KV, et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion. J Clin Invest. 2013;123:236–246.
   PubMed Web of Science ®Google Scholar
• Knauf F, Asplin JR, Granja I, et al. NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int. 2013;84:895–901.
   PubMed Web of Science ®Google Scholar
• Mandrile G, van Woerden CS, Berchialla P, et al. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int. 2014;86:1197–1204.
   PubMed Web of Science ®Google Scholar
• Hoppe B, Kemper MJ, Bökenkamp A, et al. Plasma calcium-oxalate saturation in children with renal insufficiency and in children with primary hyperoxaluria. Kidney Int. 1998;54:921–925.
   PubMed Web of Science ®Google Scholar
• Perinpam M, Enders FT, Mara KC, et al. Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease. Clin Biochem. 2017;50:1014–1019.
   PubMed Web of Science ®Google Scholar
• Hopp K, Cogal AG, Bergstralh EJ, et al. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol. 2015;26:2559–2570.
   PubMed Web of Science ®Google Scholar
• Richard E, Blouin J-M, Harambat J, et al. Late diagnosis of primary hyperoxaluria type III. Ann Clin Biochem. 2017;54:406–411.
   PubMed Web of Science ®Google Scholar
• Fargue S. Factors influencing clinical outcome in patients with primary hyperoxaluria type 1. Kidney Int. 2014;86:1074–1076.
   PubMed Web of Science ®Google Scholar
• Edvardsson VO, Goldfarb DS, Lieske JC, et al. Hereditary causes of kidney stones and chronic kidney disease. Pediatr Nephrol. 2013;28:1923–1942.
   PubMed Web of Science ®Google Scholar
• Cochat P, Hulton S-A, Acquaviva C, et al. Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant. 2012;27:1729–1736.
   PubMed Web of Science ®Google Scholar
• Hoyer-Kuhn H, Kohbrok S, Volland R, et al. Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice. Clin J Am Soc Nephrol. 2014;9:468–477.
   PubMed Web of Science ®Google Scholar
• Pey AL, Albert A, Salido E. Protein homeostasis defects of alanine-glyoxylate aminotransferase: new therapeutic strategies in primary hyperoxaluria type I. BioMed Res Int. 2013;2013:687658.
   PubMedGoogle Scholar
• Cellini B, Montioli R, Oppici E, et al. The chaperone role of the pyridoxal 5ʹ-phosphate and its implications for rare diseases involving B6-dependent enzymes. Clin Biochem. 2014;47:158–165.
   PubMed Web of Science ®Google Scholar
• Dindo M, Oppici E, Dell’Orco D, et al. Correlation between the molecular effects of mutations at the dimer interface of alanine–glyoxylate aminotransferase leading to primary hyperoxaluria type I and the cellular response to vitamin B6. J Inherit Metab Dis. 2018;41:263–275.
   PubMed Web of Science ®Google Scholar
• Leumann E, Hoppe B, Neuhaus T. Management of primary hyperoxaluria: efficacy of oral citrate administration. Pediatr Nephrol. 1993;7:207–211.
   PubMed Web of Science ®Google Scholar
• Pak CY, Heller HJ, Pearle MS, et al. Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions. J Urol. 2003;169:465–469.
   PubMed Web of Science ®Google Scholar
• Milliner DS, Eickholt JT, Bergstralh EJ, et al. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med. 1994;331:1553–1558.
   PubMed Web of Science ®Google Scholar
• Zimmermann DJ, Voss S, Von Unruh GE, et al. Importance of magnesium in absorption and excretion of oxalate. Urol Int. 2005;74:262–267.
   PubMed Web of Science ®Google Scholar
• Wong K, Thomson C, Bailey RR, et al. Acute oxalate nephropathy after a massive intravenous dose of vitamin C. Aust N Z J Med. 1994;24:410–411.
   PubMedGoogle Scholar
• Marangella M, Vitale C, Cosseddu D, et al. Effects of oral and intravenous calcitriol on serum calcium oxalate saturation in dialysis patients. Clin Sci (Lond). 1993;85:309–314.
   PubMed Web of Science ®Google Scholar
• Siener R, Hoppe B, Löhr P, et al. Metabolic profile and impact of diet in patients with primary hyperoxaluria. Int Urol Nephrol. 2018;50:1583–1589.
   PubMed Web of Science ®Google Scholar
• Illies F, Bonzel K-E, Wingen A-M, et al. Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int. 2006;70:1642–1648.
   PubMed Web of Science ®Google Scholar
• Hoppe B, Graf D, Offner G, et al. Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure. Pediatr Nephrol. 1996;10:488–492.
   PubMed Web of Science ®Google Scholar
• Compagnon P, Metzler P, Samuel D, et al. Long-term results of combined liver-kidney transplantation for primary hyperoxaluria type 1: the French experience. Liver Transpl. 2014;20:1475–1485.
   PubMed Web of Science ®Google Scholar
• Filler G, Hoppe B. Combined liver-kidney transplantation for hyperoxaluria type II? Pediatr Transplant. 2014;18:237–239.
   Web of Science ®Google Scholar
• Dhondup T, Lorenz EC, Milliner DS, et al. Combined liver-kidney transplantation for primary hyperoxaluria type 2: a case report. Am J Transplant. 2018;18:253–257.
   PubMed Web of Science ®Google Scholar
• Siener R, Bangen U, Sidhu H, et al. The role of Oxalobacter formigenes colonization in calcium oxalate stone disease. Kidney Int. 2013;83:1144–1149.
   PubMed Web of Science ®Google Scholar
• Iyalomhe O, Khantwal CM, Kang DC. The structure and function of OxlT, the oxalate transporter of Oxalobacter formigenes. J Membr Biol. 2015;248:641–650.
   PubMed Web of Science ®Google Scholar
• Knauf F, Ko N, Jiang Z, et al. Net intestinal transport of oxalate reflects passive absorption and SLC26A6-mediated secretion. J Am Soc Nephrol. 2011;22:2247–2255.
   PubMed Web of Science ®Google Scholar
• Hoppe B, Beck B, Gatter N, et al. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int. 2006;70:1305–1311.
   PubMed Web of Science ®Google Scholar
• Hoppe B, Niaudet P, Salomon R, et al. A randomised phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Pediatr Nephrol. 2017;32:781–790.
   PubMed Web of Science ®Google Scholar
• OxThera. A Phase 2 Open-label Multi-centre Study to Evaluate the Efficacy and Safety of Oxabact® to Reduce Plasma Oxalate in Subjects With Primary Hyperoxaluria Who Are on Dialysis [Internet]. NCT02000219. 2013. p. 2018. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02000219.
   Google Scholar
• Hoppe B, Dehmel B, Herberg U. Efficacy and safety of Oxabact® OC5 in dialysis patients with primary hyperoxaluria type 1 (PH1): a phase II, prospective, open-label study. Poster session presented at: dyalisis, dyalisate and clearance. Am Soc Nephrol Kidney Week. 2018. San Diego, CA, USA
   Google Scholar
• OxThera. A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria [Internet]. NCT03116685. 2018. p. 2018. Available from: https://clinicaltrials.gov/show/NCT03116685.
   Google Scholar
• Langman CB, Grujic D, Pease RM, et al. A double-blind, Placebo controlled, randomized phase 1 cross-over study with ALLN-177, an orally administered oxalate degrading enzyme. Am J Nephrol. 2016;44:150–158.
   PubMed Web of Science ®Google Scholar
• Allena Pharmaceuticals. Pilot Study of ALLN-177 in Adult and Pediatric Subjects Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia [Internet]. NCT03391804. 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03391804.
   Google Scholar
• Zou G-M. RNAi technique in stem cell research: current status and future perspectives. Methods Mol Biol. 2017;1622:3–14.
   PubMedGoogle Scholar
• Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432:173–178.
   PubMed Web of Science ®Google Scholar
• Liebow A, Li X, Racie T, et al. An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria. J Am Soc Nephrol. 2017;28:494–503.
   PubMed Web of Science ®Google Scholar
• Alnylam Pharmaceuticals. Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1) [Internet]. Press release. 2018. Available from: http://investors.alnylam.com/news-releases/news-release-details/alnylam-reports-updated-positive-results-phase-12-study.
   Google Scholar
• Alnylam Pharmaceuticals. Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 [Internet]. Press release. 2018. Available from: http://investors.alnylam.com/news-releases/news-release-details/alnylam-reports-updated-positive-results-phase-12-study-0.
   Google Scholar
• Alnylam Pharmaceuticals. A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients With Primary Hyperoxaluria Type 1 [Internet]. NCT03350451. 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03350451.
   Google Scholar
• Dicerna Pharmaceuticals. Dicerna Prioritizes Resources to Advance GalXC^TM Product Candidates [Internet]. Press release. 2016. Available from: http://investors.dicerna.com/news-releases/news-release-details/dicerna-prioritizes-resources-advance-galxctm-product-candidates.
   Google Scholar
• Dicerna Pharmaceuticals. A Phase 1 Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1) [Internet]. NCT02795325. 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02795325.
   Google Scholar
• Dicerna Pharmaceuticals. A Placebo-Controlled, Single-Blind, Single-Center Phase 1 Study in Normal Healthy Volunteers and Open-Label Multi-Center Study in Patients With Primary Hyperoxaluria to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Asc [Internet]. NCT03392896. 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03392896.
   Google Scholar
• Dicerna Pharmaceuticals. Dicerna Files Clinical Trial Application for DCR-PHXC, the Company’s Most Advanced GalXC^TM Product Candidate, for Phase 1 Study in Primary Hyperoxaluria (PH) [Internet]. Press release. 2017. Available from: http://investors.dicerna.com/news-releases/news-release-details/dicerna-files-clinical-trial-application-dcr-phxc-companys-most.
   Google Scholar
• Dicerna Pharmaceuticals. Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial [Internet]. Press release. 2018. Available from: http://investors.dicerna.com/news-releases/news-release-details/dicerna-doses-first-primary-hyperoxaluria-patient-dcr-phxc-group.
   Google Scholar
• Dicerna Pharmaceuticals. Dicerna Announces Proof of Concept for DCR-PHXC in the Treatment of Primary Hyperoxaluria [Internet]. Press release. 2018. Available from: http://investors.dicerna.com/news-releases/news-release-details/dicerna-announces-proof-concept-dcr-phxc-treatment-primary.
   Google Scholar
• Darisipudi MN, Knauf F. An update on the role of the inflammasomes in the pathogenesis of kidney diseases. Pediatr Nephrol. 2016;31:535–544.
   PubMed Web of Science ®Google Scholar
• Mulay SR, Shi C, Ma X, et al. Novel insights into crystal-induced kidney injury. Kidney Dis (Basel, Switzerland). 2018;4:49–57.
   PubMed Web of Science ®Google Scholar
• Ermer T, Eckardt K-U, Aronson PS, et al. Oxalate, inflammasome, and progression of kidney disease. Curr Opin Nephrol Hypertens. 2016;25:363–371.
   PubMed Web of Science ®Google Scholar
• Anders H-J, Suarez-Alvarez B, Grigorescu M, et al. The macrophage phenotype and inflammasome component NLRP3 contributes to nephrocalcinosis-related chronic kidney disease independent from IL-1-mediated tissue injury. Kidney Int. 2018;93:656–669.
   PubMed Web of Science ®Google Scholar
• Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13:397–411.
   PubMed Web of Science ®Google Scholar
• Ludwig-Portugall I, Bartok E, Dhana E, et al. An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice. Kidney Int. 2016;90:525–539.
   PubMed Web of Science ®Google Scholar
• Marchetti C, Swartzwelter B, Gamboni F, et al. OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci U S A. 2018;115:E1530–E1539.
   PubMed Web of Science ®Google Scholar
• Danpure CJ, Cooper PJ, Wise PJ, et al. An enzyme trafficking defect in two patients with primary hyperoxaluria type 1: peroxisomal alanine/glyoxylate aminotransferase rerouted to mitochondria. J Cell Biol. 1989;108:1345–1352.
   PubMed Web of Science ®Google Scholar
• Miyata N, Steffen J, Johnson ME, et al. Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1. Proc Natl Acad Sci. 2014;111:14406–14411.
   PubMed Web of Science ®Google Scholar
• Hou S, Madoux F, Scampavia L, et al. Drug library screening for the identification of ionophores that correct the mistrafficking disorder associated with oxalosis kidney disease. SLAS Discov. 2017;22:887–896.
   PubMed Web of Science ®Google Scholar
• Oppici E, Fargue S, Reid ES, et al. Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine: glyoxylateaminotransferase causing primary hyperoxaluria type I. Hum Mol Genet. 2015;24:5500–5511.
   PubMed Web of Science ®Google Scholar
• Oppici E, Montioli R, Dindo M, et al. The chaperoning activity of amino-oxyacetic acid on folding-defective variants of human alanine: glyoxylateaminotransferase causing primary hyperoxaluria type I. ACS Chem Biol. 2015;10:2227–2236.
   PubMed Web of Science ®Google Scholar
• Madoux F, Janovick JA, Smithson D, et al. Development of a phenotypic high-content assay to identify pharmacoperone drugs for the treatment of primary hyperoxaluria type 1 by high-throughput screening. Assay Drug Dev Technol. 2015;13:16–24.
   PubMed Web of Science ®Google Scholar
• Belostotsky R, Lyakhovetsky R, Sherman MY, et al. Translation inhibition corrects aberrant localization of mutant alanine-glyoxylate aminotransferase: possible therapeutic approach for hyperoxaluria. J Mol Med (Berl). 2018;96:621–630.
   PubMed Web of Science ®Google Scholar
• Martin-Higueras C, Luis-Lima S, Salido E. Glycolate oxidase is a safe and efficient target for substrate reduction therapy in a mouse model of primary hyperoxaluria type I. Mol Ther. 2016;24:719–725.
   PubMed Web of Science ®Google Scholar
• Moya-Garzón MD, Martín Higueras C, Peñalver P, et al. Salicylic acid derivatives inhibit oxalate production in mouse hepatocytes with primary hyperoxaluria type 1. J Med Chem. 2018;61:7144–7167.
   PubMed Web of Science ®Google Scholar
• Zabaleta N, Barberia M, Martín-Higueras C, et al. CRISPR/Cas9-mediated disruption of glycolate oxidase is an efficacious and safe treatment for primary hyperoxaluria type I. Mol Ther. 2018;26:384–385.
   Web of Science ®Google Scholar
• Zapata-Linares N, Rodriguez S, Salido E, et al. Generation and characterization of human iPSC lines derived from a primary hyperoxaluria type I patient with p.I244T mutation. Stem Cell Res. 2016;16:116–119.
   PubMed Web of Science ®Google Scholar
• Martin-Higueras C, Torres A, Salido E. Molecular therapy of primary hyperoxaluria. J Inherit Metab Dis. 2017;40:481–489.
   PubMed Web of Science ®Google Scholar
• Mulay SR, Eberhard JN, Desai J, et al. Hyperoxaluria requires TNF receptors to initiate crystal adhesion and kidney stone disease. J Am Soc Nephrol. 2017;28:761–768.
   PubMed Web of Science ®Google Scholar
• Verhulst A, Asselman M, Persy VP, et al. Crystal retention capacity of cells in the human nephron: involvement of CD44 and its ligands hyaluronic acid and osteopontin in the transition of a crystal binding- into a nonadherent epithelium. J Am Soc Nephrol. 2003;14:107–115.
   PubMed Web of Science ®Google Scholar
• Salido EC, Li XM, Lu Y, et al. Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer. Proc Natl Acad Sci U S A. 2006;103:18249–18254.
   PubMed Web of Science ®Google Scholar
• Salido E, Rodriguez-Pena M, Santana A, et al. Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer. Mol Ther. 2011;19:870–875.
   PubMed Web of Science ®Google Scholar
• Toscano MG, van der Velden J, van der Werf S, et al. Generation of a vero-based packaging cell line to produce SV40 gene delivery vectors for use in clinical gene therapy studies. Mol Ther Methods Clin Dev. 2017;6:124–134.
   PubMed Web of Science ®Google Scholar
• Toscano MG, de Haan P. How Simian Virus 40 hijacks the intracellular protein trafficking pathway to its own benefit … and ours. Front Immunol. 2018;9:1160.
   PubMed Web of Science ®Google Scholar